SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: semi_infinite who wrote (11681)9/19/2018 2:31:24 PM
From: Miljenko Zuanic   of 12215
 
< Just wondering if similar unresolved metabolite peaks were detected with MGL3196.>

I think I mentioned early that I did not investigated early pre-clinical/clinical development for 3196. It was Roche compounds and work, so literature may be scarce. I may do it in future, and outcome of my DD will be presented here.

3196 possess dihydropyridazine moiety, while 2809 has phenolic moiety, significant difference in metabolite formation....that can potentially form base for liver toxicity. All this is "theoretical" for 2809, until prove opposite.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News